Novartis drafts TV celeb Nick Cannon to talk up importance of flu vaccines

Nick Cannon

Novartis ($NVS) may be selling off most of its vaccines business to GlaxoSmithKline ($GSK), but for now, it's hanging onto its flu vaccines. And to help show Americans just how important those flu vaccines are, it's teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu. More from FiercePharmaMarketing

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.